Introduction
Neonatal-onset multisystem inflammatory disease (NOMID), also known as chronic infantile neurological, cutaneous, and articular (CINCA) syndrome, is a rare autoinflammatory disorder characterized by early-onset, persistent inflammation affecting multiple organ systems.
What Is Neonatal Onset Multisystem Inflammatory Disease?
Neonatal-onset multisystem inflammatory disease (NOMID), also known as chronic infantile neurological, cutaneous, and articular (CINCA) syndrome, has various clinical symptoms affecting various organ systems. The cardinal features of NOMID include fever, chronic urticarial rash, joint inflammation, and central nervous system (CNS) involvement.
Fever: It is a common and persistent symptom in NOMID patients. It is usually present from birth and persists throughout the individual's life. The fever is often accompanied by other systemic manifestations.
Chronic Urticarial Rash: One of the distinguishing characteristics of NOMID is the presence of a chronic, non-itchy urticarial rash. This rash typically appears shortly after birth or within the first few weeks of life. It can manifest as erythematous papules, plaques, or maculopapular lesions. The rash tends to be symmetrical and can involve the face, trunk, and extremities.
Joint Inflammation: Joint involvement is a prominent feature of NOMID. Affected individuals may experience joint pain, swelling, and tenderness. The joints commonly affected include the knees, ankles, wrists, and elbows. The inflammation can persist and lead to long-term joint damage if left untreated.
Central Nervous System (CNS) Involvement: CNS manifestations are a significant aspect of NOMID and can vary in severity. Patients may present with headaches, meningitis, irritability, and developmental delay. Chronic inflammation within the CNS can lead to more severe complications, such as hydrocephalus, optic nerve atrophy, and hearing loss. These neurological abnormalities can significantly impact the patient's quality of life.
Ophthalmic Involvement: Ophthalmic manifestations are common in NOMID. Individuals may develop conjunctivitis, uveitis (inflammation of the uvea), and episcleritis (inflammation of the episclera). If left untreated, these ocular manifestations can cause redness, pain, and blurred vision.
Auditory Abnormalities: Hearing loss can occur in NOMID due to recurrent otitis media, chronic middle ear inflammation, or direct involvement of the auditory nerves. It is crucial to monitor hearing function regularly to identify and manage any hearing impairment promptly.
Growth and Developmental Delay: Some NOMID patients may experience growth delays and developmental abnormalities. These can include delays in reaching developmental milestones, cognitive impairments, and learning difficulties. Early intervention and appropriate support services are essential to optimizing the developmental outcomes of affected children.
It is important to note that the severity and progression of NOMID symptoms can vary among individuals. Some patients may have milder disease manifestations, while others can experience more severe symptoms.
What Is the Pathophysiology of NOMID?
NOMID is caused by gain-of-function mutations in the NLRP3 gene, which encodes the NACHT, LRR, and PYD domain-containing protein 3, also known as cryopyrin. These mutations result in the overactivation of the inflammasome complex and excessive production of interleukin-1β (IL-1β), a key mediator of inflammation. The dysregulated inflammatory response leads to the characteristic clinical features observed in NOMID patients.
How Is Neonatal Onset Multisystem Inflammatory Disease Diagnosed?
Diagnosing NOMID requires a combination of clinical findings, laboratory investigations, and genetic testing. Physicians should carefully assess typical symptoms, such as chronic urticarial rash, joint inflammation, and CNS involvement. Laboratory tests may reveal elevated acute-phase reactants, including C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). However, these markers can be non-specific and fluctuate over time.
Genetic testing plays a crucial role in confirming the diagnosis of NOMID. Sequencing of the NLRP3 gene can identify the pathogenic mutations responsible for the condition. The identification of a causative mutation not only helps establish the diagnosis but also enables genetic counseling and potential family screening.
How Is Neonatal Onset Multisystem Inflammatory Disease Managed?
The management of Neonatal-Onset Multisystem Inflammatory Disease (NOMID) aims to control symptoms, reduce inflammation, prevent long-term adverse effects, and improve the quality of life for affected individuals. The treatment approach typically involves a combination of pharmacological interventions and supportive measures.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): NSAIDs, such as Ibuprofen and Indomethacin, are commonly used as first-line treatments for NOMID. They help to reduce inflammation, alleviate symptoms like fever and joint pain, and improve overall well-being. However, NSAIDs may not provide sufficient control of symptoms in more severe cases of NOMID.
Corticosteroids: Prednisone or prednisolone can be prescribed to patients with NOMID who do not respond adequately to NSAIDs alone. Corticosteroids have potent anti-inflammatory effects and can help reduce systemic inflammation. However, their long-term use is associated with significant side effects, including weight gain, growth suppression, osteoporosis, and increased risk of infections.
IL-1β Inhibitors: The advent of IL-1β inhibitors has revolutionized the treatment of NOMID and significantly improved outcomes for affected individuals. The two main IL-1β inhibitors used in NOMID are:
-
Anakinra: Anakinra is a recombinant IL-1 receptor antagonist that competitively blocks the activity of IL-1β. Anakinra has shown remarkable efficacy in reducing inflammation, and adverse symptoms, improving the quality of life for NOMID patients. It is generally well-tolerated, with common side effects, including injection site reactions and flu-like symptoms.
-
Canakinumab: Canakinumab is a monoclonal antibody that specifically targets IL-1β. It is given as a subcutaneous injection every 4 to 8 weeks, depending on the patient's response. Canakinumab has demonstrated excellent efficacy in controlling inflammation and reducing disease activity in NOMID. It offers the advantage of less frequent dosing compared to anakinra. Side effects may include injection site reactions, upper respiratory tract infections, and gastrointestinal disturbances.
Supportive Measures:
-
Physiotherapy and Occupational Therapy: Physiotherapy and occupational therapy are crucial in managing joint inflammation and preserving joint function. These therapies help maintain joint mobility, improve muscle strength, and enhance functional independence.
-
Ophthalmological and Audiological Evaluations: Regular ophthalmological and audiological assessments are essential for monitoring and managing potential eye and ear complications. Prompt identification and treatment of ocular and auditory abnormalities can help prevent further deterioration and optimize outcomes.
-
Genetic Counseling: It should be offered to individuals with NOMID and their families. This explains the genetic basis of the condition, recurrence risks, and family planning options.
-
Psychological Support: Living with a chronic condition like NOMID can have significant emotional and social impacts on patients and their families. Psychological support, including counseling and support groups, can help address these challenges, enhance coping strategies, and improve overall well-being.
Conclusion
Neonatal-onset multisystem inflammatory disease (NOMID) is a rare autoinflammatory disorder characterized by early-onset, persistent inflammation affecting multiple organ systems. The treatment of NOMID involves a combination of pharmacological interventions, such as NSAIDs and corticosteroids. Overall, the comprehensive management of NOMID requires a multidisciplinary approach involving rheumatologists, dermatologists, ophthalmologists, audiologists, genetic counselors, and psychologists.
